Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | PF-06801591 + PF-08052667 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| PF-06801591 | PF06801591|PF 06801591|Sasanlimab | Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 132 | PF-06801591 (sasanlimab) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (PMID: 32847983). | |
| PF-08052667 | PF08052667|PF 08052667 | Limited information is currently available on PF-08052667 (Oct 2025). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07206225 | Phase I | PF-08052667 BCG solution + PF-06801591 + PF-08052667 PF-06801591 + PF-08052667 | A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer | Recruiting | USA | ISR | GBR | FRA | ESP | 1 |